Support for industry on clinical data publication

The European Medicines Agency (EMA) has developed detailed guidance for pharmaceutical companies on the requirements to comply with its policy on the publication of clinical data.

Clinical data publication temporarily suspended

As of 1 August 2018, EMA has suspended all new activities related to the publication of clinical data. This is a result of the implementation of the third phase of EMA's business continuity plan to prepare for its relocation to the Netherlands.

EMA has stopped sending 'invitation letters' and is contacting companies to cancel new submissions due after 1 August 2018. EMA will contact applicants prior to the restart of clinical data publication, once its relocation is completed.

By the end of October 2018, EMA will publish all clinical data submitted before 1 August 2018 (corresponding to regulatory procedures finalised in December 2016).

Guidance and templates

EMA first published guidance in March 2016 and is updating it on a regular basis. Current and past versions of the guidance as well as the list of changes between published versions can be found below:

The external guidance provides further information on:

  • the scope of the policy as regards clinical reports submitted as part of other regulatory procedures, informed consent applications and duplicate marketing authorisations, as well as definitions (in chapter 1);
  • the procedural aspects related to the submission of clinical reports (in chapter 2);
  • anonymising clinical reports (in chapter 3), including a template for the anonymisation report (in annex 1.2);
  • how to identify and redact commercially confidential information in clinical reports (in chapter 4).

Companies should provide justifications for redactions of commercially confidential information by using the following template:

EMA has developed a questions-and-answers (Q&A) document to expand on issues addressed in the external guidance and in discussions with applicants. It addresses a number of questions concerning procedural matters including timelines, commercially confidential information and the anonymisation process. For more information, see:

It will be revised regularly to reflect updates.

Stakeholder meetings

EMA also held a series of briefings and consultations to support stakeholders in implementing the policy:

Agendas, meeting reports, presentations, question-and-answer documents and available video recordings are provided on the meeting pages.

Micro, small and medium-sized enterprises

Micro, small and medium-sized enterprises (SMEs) are entitled to a free redaction tool license valid for a period of 12 months to allow companies enough time to prepare the final redacted version. The application letter template for the free redaction tool is available in annex 1 of the external guidance.

SMEs should contact the SME office 5 months prior to the CHMP opinion to apply for the free redaction tool license. The SME office can also provide further guidance on the EMA's policy on the publication of clinical data.

How useful was this page?

Add your rating